Stock Track | Maravai LifeSciences Soars 17.26% After-Hours on Strong Q1 Results and Raised Guidance

Stock Track04:32

Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant after-hours surge of 17.26% on Thursday, following the release of its first-quarter financial results.

The company reported quarterly revenue of $65.8 million, a 40.5% year-over-year increase that substantially beat analyst consensus estimates of $53 million. Adjusted EBITDA swung to a positive $20.3 million, far exceeding expectations of $4.04 million. The strong performance was primarily driven by a 65% year-over-year increase in TriLink revenue, fueled by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs.

Maravai also raised its full-year 2026 guidance, increasing revenue expectations to $205-$215 million from $200-$210 million and boosting adjusted EBITDA outlook to $30-$32 million from $18-$20 million. The company highlighted improved operational efficiency and positive free cash flow generation as additional positive factors contributing to the bullish investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138294934?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138294934","market":"nz","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Soars 17.26% After-Hours on Strong Q1 Results and Raised Guidance","media":"Stock Track","content":"<p>Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant after-hours surge of 17.26% on Thursday, following the release of its first-quarter financial results.</p><p>The company reported quarterly revenue of $65.8 million, a 40.5% year-over-year increase that substantially beat analyst consensus estimates of $53 million. Adjusted EBITDA swung to a positive $20.3 million, far exceeding expectations of $4.04 million. The strong performance was primarily driven by a 65% year-over-year increase in TriLink revenue, fueled by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs.</p><p>Maravai also raised its full-year 2026 guidance, increasing revenue expectations to $205-$215 million from $200-$210 million and boosting adjusted EBITDA outlook to $30-$32 million from $18-$20 million. The company highlighted improved operational efficiency and positive free cash flow generation as additional positive factors contributing to the bullish investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Soars 17.26% After-Hours on Strong Q1 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Soars 17.26% After-Hours on Strong Q1 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant after-hours surge of 17.26% on Thursday, following the release of its first-quarter financial results.</p><p>The company reported quarterly revenue of $65.8 million, a 40.5% year-over-year increase that substantially beat analyst consensus estimates of $53 million. Adjusted EBITDA swung to a positive $20.3 million, far exceeding expectations of $4.04 million. The strong performance was primarily driven by a 65% year-over-year increase in TriLink revenue, fueled by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs.</p><p>Maravai also raised its full-year 2026 guidance, increasing revenue expectations to $205-$215 million from $200-$210 million and boosting adjusted EBITDA outlook to $30-$32 million from $18-$20 million. The company highlighted improved operational efficiency and positive free cash flow generation as additional positive factors contributing to the bullish investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1138294934","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138294934","pubTimestamp":1778185965,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant after-hours surge of 17.26% on Thursday, following the release of its first-quarter financial results.The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"个股赛道|Maravai LifeSciences盘后大涨17.26%，Q1业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Maravai LifeSciences Holdings, Inc. (MRVI) experienced a significant after-hours surge of 17.26% on Thursday, following the release of its first-quarter financial results.The company reported quarterly revenue of $65.8 million, a 40.5% year-over-year increase that substantially beat analyst consensus estimates of $53 million. Adjusted EBITDA swung to a positive $20.3 million, far exceeding expectations of $4.04 million. The strong performance was primarily driven by a 65% year-over-year increase in TriLink revenue, fueled by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs.Maravai also raised its full-year 2026 guidance, increasing revenue expectations to $205-$215 million from $200-$210 million and boosting adjusted EBITDA outlook to $30-$32 million from $18-$20 million. The company highlighted improved operational efficiency and positive free cash flow generation as additional positive factors contributing to the bullish investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138294934","isCrawlerRequest":true}